Adjuvant Chemotherapy Timing in Colorectal Cancer

The timing of adjuvant chemotherapy following curative resection of colorectal cancer has emerged as a critical determinant of long-term outcomes. Prompt initiation aims to eradicate microscopic residual disease at a point of minimal tumour burden, thereby reducing recurrence risk. International guidelines commonly recommend commencement within six to eight weeks post-surgery, balancing the need for tissue healing and patient recovery against the risk of tumour regrowth. However, real-world practice exhibits considerable variability. Factors such as postoperative complications, referral pathways, socioeconomic barriers and institutional infrastructure can cause delays, potentially undermining survival benefits. Emerging evidence underscores that even modest delays beyond eight weeks are associated with incremental declines in both disease-free and overall survival, whereas ultra-early initiation—within two weeks—may be feasible and safe in selected patients. Contemporary research continues to refine the optimal window for chemotherapy onset, seeking to personalise timing according to patient fitness, tumour biology and health-system efficiencies.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Adjuvant Chemotherapy Timing in Colorectal Cancer publication trend

The graph below shows the total number of articles in adjuvant chemotherapy timing in colorectal cancer across all publications each year (not limited to Nature Index journals).

Technical terms

Adjuvant chemotherapy: Systemic drug treatment administered after primary surgical resection to eliminate residual microscopic tumour cells.

Disease-free survival (DFS): The interval from the date of surgical intervention to the first occurrence of cancer recurrence or death from any cause.

Overall survival (OS): The duration from treatment initiation until death from any cause, used as a key endpoint in oncology trials.

FOLFOX: A chemotherapy regimen combining folinic acid (leucovorin), fluorouracil (5-FU) and oxaliplatin, commonly used in colorectal cancer management.

References

1. Short-term outcomes of Early versus conventional adjuvant chemotherapy in stage III colon cancer: randomized clinical trial. BJS Open (2023).
2. Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study. BMC Cancer (2018).
3. Timing of Adjuvant Chemotherapy and Survival in Colorectal, Gastric, and Pancreatic Cancer. A Systematic Review and Meta-Analysis. Cancers (2019).
4. Factors Affecting Use and Delay (≥8 Weeks) of Adjuvant Chemotherapy after Colorectal Cancer Surgery and the Impact of Chemotherapy-Use and Delay on Oncologic Outcomes. PLOS ONE (2015).
5. The impact of delayed commencement of adjuvant chemotherapy (eight or more weeks) on survival in stage II and III colon cancer: a national population-based cohort study. Oncotarget (2017).
6. The Aetiology of Delay to Commencement of Adjuvant Chemotherapy following Colorectal Resection. International Journal of Surgical Oncology (2014).
7. The optimal time of starting adjuvant chemotherapy after curative surgery in patients with colorectal cancer. BMC Cancer (2023).